ProCE Banner Activity

Expert Commentary on the Evolving Management of Hereditary Angioedema

Clinical Thought

The evolving management landscape of hereditary angioedema has led to unmet needs in care and questions regarding optimal treatment selection. Here, I review new and emerging therapies and provide guidance on transitions of care and shared decision-making.

Released: February 19, 2025

Expiration: February 18, 2026

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Ionis Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Faculty Disclosure

Primary Author

Marc Riedl, MD, MS

Professor of Medicine
HAE Community Endowed Chair
Clinical Director, US HAEA Angioedema Center
Clinical Service Chief, Division of Allergy & Immunology
University of California, San Diego
La Jolla, California

Marc Riedl, MD, MS: researcher: Astria, Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda; consultant/advisor/speaker: Astria, Biocryst, Biomarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, Kalvista, Novartis, Pharming, Pharvaris, Sanofi/Regeneron, Takeda.